Nasdaq · Healthcare
Opus Genetics, Inc. (IRD)
As-reported financials and recent SEC filings for Opus Genetics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$14.2M
Net income
$-49.6M
Net margin
—
Diluted EPS
$-0.80
ROE
-323.1%
P/E (TTM)
—
Market cap
—
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 |
| Gross profit | — | — | — | — | — |
| Operating income | $-38.6M | $-62.1M | $-10.6M | $18.2M | $-22.7M |
| Net income | $-49.6M | $-57.5M | $-10.0M | $17.9M | $-56.7M |
| Diluted EPS | $-0.80 | $-1.07 | $-0.23 | $0.43 | $-1.91 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
424B22026-06-17
View on EDGAR →8-K2026-06-16
View on EDGAR →8-K2026-06-16
View on EDGAR →EFFECT2026-06-15
View on EDGAR →S-32026-06-05
View on EDGAR →42026-05-20
View on EDGAR →SCHEDULE 13D/A2026-05-20
View on EDGAR →SCHEDULE 13G2026-05-15
View on EDGAR →Largest Healthcare peers
Go deeper on IRD
Search Opus Genetics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.